Important: Product recall - Emerade

Dear Healthxchange customers,

On the 9th of May 2023, we received notification from the MHRA regarding the recall of the following products due to the potential for device failure:

  • Emerade 500 micrograms auto-injectors
  • Emerade 300 micrograms auto-injectors

You can read a copy of this communication here.

Protecting the safety and well-being of our customers and patients, as well as guaranteeing the highest quality product efficacy, is always our first priority.

As a result, we immediately quarantined all remaining stock and ceased supplying the impacted products.

Next actions

  1. We ask that all account holders please ensure that any patients are reviewed by their prescriber, to determine whether their adrenaline auto-injector prescription is still appropriate and in line with existing guidance.
  2. Where necessary, we ask that you request a new prescription to replace each auto-injector with an adrenaline pen of an alternative brand. Epipen 300 or Jext 300 are appropriate alternatives to Emerade 500 micrograms. Dosing recommendations are available in the Summary of Product Characteristics (SmPC).
  3. Please inform your patients to return Emerade 500 micrograms and Emerade 300 micrograms auto-injectors to any pharmacy after they have obtained two equivalent-strength adrenaline pens of an alternative brand.

Our customer services team can support you with any enquiries or further actions. If you have questions regarding this email, please contact 0330 995 7999 or email orders@healthxchange.com.

We apologise in advance for any inconvenience caused.

Sincerely,

Richard Ghanty BPharm MRPharmS
Director for UK Pharmacy Services
Healthxchange Pharmacy UK Limited